No Data
No Data
BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) 26% Share Price Surge Not Quite Adding Up
BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) shares have continued their recent momentum with a 26% gain in the last month alone. The last 30 days bring the annual gain to a very sharp
BrightGene to Sell 500 Million Yuan Shares to Actual Controller; Shares Up 3%
BrightGene Bio-Medical Technology (SHA:688166) plans to raise about 500 million yuan from the sale of shares to one of its actual controllers, according to a Tuesday filing on the Shanghai Stock Excha
Gelonghui Announcements Selected | Borui Pharmaceutical: Plans to raise no more than 500 million yuan in capital from actual controllers; Shengda Biotech: “Demonstration of full biosynthesis technology and green manufacturing for major vitamin products” p
[Hot Focus] Zhengdan Shares (300641.SZ): Serious abnormal fluctuations in stock and convertible bond trading Zhengdan Shares (300641.SZ) announced that trading prices of the company's shares and convertible bonds have fluctuated greatly recently. In order to protect investors' interests, the company will conduct suspension checks on recent abnormal fluctuations in stock and convertible bond transactions. Following the application, trading of the company's shares (stock abbreviation: Zhengdan shares, stock code: 300641) and convertible bonds (bond abbreviation: Zhengdan Convertible Bonds, bond code: 123106) will be suspended from the opening of the market on May 7, 2024, pending the company's completion of relevant inspections
Borui Pharmaceutical (688166.SH): Net profit of 640.69,900 yuan in the first quarter decreased by 9.47% year-on-year
On April 27, Ge Longhui Pharmaceutical (688166.SH) released its report for the first quarter of 2024, achieving operating income of 340 million yuan, an increase of 11.54%; net profit attributable to shareholders of listed companies of 640.699 million yuan, a year-on-year decrease of 9.47%; net profit attributable to shareholders of listed companies after deducting non-recurring profits and losses of 64.214,400 yuan, a year-on-year decrease of 7.89%; and basic earnings per share of 0.15 yuan.
BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) 5.8% Gain Last Week Benefited Both Retail Investors Who Own 34% as Well as Insiders
Key Insights Significant control over BrightGene Bio-Medical Technology by retail investors implies that the general public has more power to influence management and governance-related decisions 51
Borui Pharmaceutical (688166.SH): Selamectin (veterinary) API obtained European CEP certificate
Glonghui, April 19 | Borui Pharmaceutical (688166.SH) announced that the active ingredient selamectin (veterinary) has received a CEP (European Pharmacopeia Suitability Certification) certificate issued by the European Medicines Quality Administration (“EDQM”). Xylamectin (veterinary use) is suitable for the treatment and prevention of parasitic infections in cats/dogs.
No Data